company background image
OVN

Oventus MedicalASX:OVN Stock Report

Last Price

AU$0.095

Market Cap

AU$23.0m

7D

14.5%

1Y

-62.0%

Updated

17 Jan, 2022

Data

Company Financials +
OVN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

OVN Stock Overview

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Oventus Medical
Historical stock prices
Current Share PriceAU$0.095
52 Week HighAU$0.28
52 Week LowAU$0.077
Beta0.50
1 Month Change15.85%
3 Month Change-17.39%
1 Year Change-62.00%
3 Year Change-68.85%
5 Year Change-87.33%
Change since IPO-86.43%

Recent News & Updates

Nov 11
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Oventus Medical Limited's (ASX:OVN) CEO For Now

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Oventus Medical Limited's (ASX:OVN) CEO For Now

Shareholders of Oventus Medical Limited ( ASX:OVN ) will have been dismayed by the negative share price return over the...

Shareholder Returns

OVNAU Medical EquipmentAU Market
7D14.5%-1.7%-0.5%
1Y-62.0%-6.5%10.4%

Return vs Industry: OVN underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.

Return vs Market: OVN underperformed the Australian Market which returned 10.4% over the past year.

Price Volatility

Is OVN's price volatile compared to industry and market?
OVN volatility
OVN Average Weekly Movement9.4%
Medical Equipment Industry Average Movement8.5%
Market Average Movement8.4%
10% most volatile stocks in AU Market15.2%
10% least volatile stocks in AU Market3.6%

Stable Share Price: OVN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: OVN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/aChris Harthttps://o2vent.com

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States. The company offers O2Vent Optima, a 3D-printed nylon oral appliance for OSA patients; and ExVent, a valve accessory that fits into the open airway of the O2Vent Optima device. The company was incorporated in 2015 and is headquartered in Indooroopilly, Australia.

Oventus Medical Fundamentals Summary

How do Oventus Medical's earnings and revenue compare to its market cap?
OVN fundamental statistics
Market CapAU$22.96m
Earnings (TTM)-AU$9.83m
Revenue (TTM)AU$1.09m

21.1x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OVN income statement (TTM)
RevenueAU$1.09m
Cost of RevenueAU$687.91k
Gross ProfitAU$401.62k
ExpensesAU$10.23m
Earnings-AU$9.83m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.041
Gross Margin36.86%
Net Profit Margin-902.36%
Debt/Equity Ratio0%

How did OVN perform over the long term?

See historical performance and comparison

Valuation

Is Oventus Medical undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OVN (A$0.1) is trading below our estimate of fair value (A$1.14)

Significantly Below Fair Value: OVN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OVN is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: OVN is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OVN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OVN is good value based on its PB Ratio (1.8x) compared to the AU Medical Equipment industry average (4.4x).


Future Growth

How is Oventus Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

94.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OVN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: OVN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OVN's is expected to become profitable in the next 3 years.

Revenue vs Market: OVN's revenue (78.3% per year) is forecast to grow faster than the Australian market (4.9% per year).

High Growth Revenue: OVN's revenue (78.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OVN's Return on Equity is forecast to be high in 3 years time (24.9%)


Past Performance

How has Oventus Medical performed over the past 5 years?

-18.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OVN is currently unprofitable.

Growing Profit Margin: OVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OVN is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.

Accelerating Growth: Unable to compare OVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OVN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: OVN has a negative Return on Equity (-77.92%), as it is currently unprofitable.


Financial Health

How is Oventus Medical's financial position?


Financial Position Analysis

Short Term Liabilities: OVN's short term assets (A$10.5M) exceed its short term liabilities (A$2.1M).

Long Term Liabilities: OVN's short term assets (A$10.5M) exceed its long term liabilities (A$359.8K).


Debt to Equity History and Analysis

Debt Level: OVN is debt free.

Reducing Debt: OVN has no debt compared to 5 years ago when its debt to equity ratio was 37.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OVN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OVN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.1% each year


Dividend

What is Oventus Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OVN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OVN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Chris Hart

3.42yrs

Tenure

AU$1,806,418

Compensation

Dr. Christopher Patrick Hart, also known as Chris, has been Chief Executive Officer and Managing Director of Oventus Medical Limited since August 30, 2018. Dr. Hart is the Co-Founder of Oventus Medical Lim...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD1.31M) is above average for companies of similar size in the Australian market ($USD291.63K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OVN's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: OVN's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.7%.


Top Shareholders

Company Information

Oventus Medical Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Oventus Medical Limited
  • Ticker: OVN
  • Exchange: ASX
  • Founded: 2015
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: AU$22.964m
  • Shares outstanding: 241.73m
  • Website: https://o2vent.com

Location

  • Oventus Medical Limited
  • 1 Swann Road
  • Suite 1
  • Indooroopilly
  • Queensland
  • 4068
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/17 16:36
End of Day Share Price2022/01/17 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.